A Phase 3 Clinical Study of KHK 4827

Kyowa Kirin

Status and phase

Completed

Phase 3

Conditions

Pustular; Psoriasis, Palmaris Et Plantaris

Psoriatic Arthritis

Psoriatic Erythroderma

Psoriasis Vulgaris

Treatments

Drug: KHK4827 210mg SC

Drug: KHK4827 140mg SC

Study type

Interventional

Funder types

Industry

Identifiers

NCT02052609

4827-005

Details and patient eligibility

About

This study is designed to evaluate the safety and efficacy of long-term exposure to KHK4827 in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic erythroderma) who have completed Study 4827-003 (Study 003)and in subjects with pustular psoriasis (generalized) or psoriatic erythroderma who have completed the Study 4827-004 (Study 004).

Enrollment

155 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject has voluntarily signed the written informed consent form to participate in this study
Subject has completed the week 52 evaluation either in Study 003 or 004

Exclusion criteria

Subject has had a serious infection, defined as requiring systemic treatment with antibiotics or antivirals (excluding oral administration)
Subject has been judged to be ineligible for participation in the study by the investigators/sub investigators